Search Results - "Asada, Shinji"

Predictive factors requiring high-dose evocalcet in hemodialysis patients with secondary hyperparathyroidism by Tokumoto, Masanori, Tokunaga, Shin, Asada, Shinji, Endo, Yuichi, Kurita, Noriaki, Fukagawa, Masafumi, Akizawa, Tadao

“…The dosage of evocalcet required to control serum parathyroid hormone (PTH) levels varies among secondary hyperparathyroidism (SHPT) patients. This post hoc…”
Get full text

Evocalcet with vitamin D receptor activator treatment for secondary hyperparathyroidism by Shigematsu, Takashi, Asada, Shinji, Endo, Yuichi, Kawata, Takehisa, Fukagawa, Masafumi, Akizawa, Tadao

“…This ad hoc analysis of a previously conducted phase 3 head-to-head comparison study of evocalcet and cinacalcet in secondary hyperparathyroidism patients…”
Get full text

Relationship between serum calcium or phosphate levels and mortality stratified by parathyroid hormone level: an analysis from the MBD-5D study by Asada, Shinji, Yokoyama, Keitaro, Miyakoshi, Chisato, Fukuma, Shingo, Endo, Yuichi, Wada, Michihito, Nomura, Takanobu, Onishi, Yoshihiro, Fukagawa, Masafumi, Fukuhara, Shunichi, Akizawa, Tadao

“…Introduction There is limited evidence about the association between calcium and phosphate levels and mortality stratified by intact parathyroid hormone (iPTH)…”
Get full text

2-Oxoadenosine induces cytotoxicity through intracellular accumulation of 2-oxo-ATP and depletion of ATP but not via the p38 MAPK pathway by Asada, Shinji, Ohta, Eiko, Akimoto, Yoriko, Abolhassani, Nona, Tsuchimoto, Daisuke, Nakabeppu, Yusaku

“…2-Oxoadenosine (2-oxo-Ado), an oxidized form of adenosine, is cytotoxic and induces growth arrest and cell death, which has potential as an anti-cancer drug…”
Get full text

Effectiveness of cinacalcet treatment for secondary hyperparathyroidism on hospitalization: Results from the MBD-5D study by Asada, Shinji, Yoshida, Kazuki, Fukuma, Shingo, Nomura, Takanobu, Wada, Michihito, Onishi, Yoshihiro, Kurita, Noriaki, Fukagawa, Masafumi, Fukuhara, Shunichi, Akizawa, Tadao

“…To elucidate the effect of cinacalcet use on all-cause and cause-specific hospitalization outcomes using a prospective cohort of maintenance hemodialysis…”
Get full text

Changes in 3-month mineral and bone disorder patterns were associated with all-cause mortality in prevalent hemodialysis patients with secondary hyperparathyroidism by Kato, Chihiro, Fujii, Naohiko, Miyakoshi, Chisato, Asada, Shinji, Onishi, Yoshihiro, Fukuma, Shingo, Nomura, Takanobu, Wada, Michihito, Fukagawa, Masafumi, Fukuhara, Shunichi, Akizawa, Tadao

“…There is limited evidence on the association between short-term changes in mineral and bone disorder parameters and survival in maintenance hemodialysis…”
Get full text

Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan by Tanaka, Tetsuhiro, Nangaku, Masaomi, Imai, Enyu, Tsubakihara, Yoshiharu, Kamai, Masatoshi, Wada, Michihito, Asada, Shinji, Akizawa, Tadao

“…Background This post-marketing surveillance (PMS) study evaluated the safety and effectiveness of long-term darbepoetin alfa (darbepoetin) for the treatment of…”
Get full text

Real-world evidence on levodopa dose escalation in patients with Parkinson's disease treated with istradefylline by Hattori, Nobutaka, Kabata, Daijiro, Asada, Shinji, Kanda, Tomoyuki, Nomura, Takanobu, Shintani, Ayumi, Mori, Akihisa

“…Istradefylline, a selective adenosine A2A receptor antagonist, is indicated in the US and Japan as adjunctive treatment to levodopa/decarboxylase inhibitors in…”
Get full text

Influence of Istradefylline Treatment on Levodopa Dose Escalation in PD Patients from over 10 Years of Experience (P7-11.001) by Hattori, Nobutaka, Kabata, Daijiro, Asada, Shinji, Kanda, Tomoyuki, Nomura, Takanobu, Shintani, Ayumi, King, Shelby, Goldstein, Ross, Mori, Akihisa

“…Abstract only…”
Get full text

Adherence to istradefylline in patients with Parkinson's disease: A group-based trajectory analysis by Fukasawa, Toshiki, Nakanishi, Etsuro, Shimoda, Hiroo, Shinoda, Katsumi, Ito, Satoru, Asada, Shinji, Yoshida, Satomi, Tanaka-Mizuno, Sachiko, Mizuno, Kayoko, Takahashi, Ryosuke, Kawakami, Koji

“…Understanding the different patterns of adherence to istradefylline treatment is essential to identifying Parkinson's disease (PD) patients who might benefit…”
Get full text

Efficacy of Evocalcet in Previously Cinacalcet-Treated Secondary Hyperparathyroidism Patients by Koiwa, Fumihiko, Tokunaga, Shin, Asada, Shinji, Endo, Yuichi, Fukagawa, Masafumi, Akizawa, Tadao

“…Evocalcet is a recently approved calcimimetic agent for secondary hyperparathyroidism (SHPT). In this study, the efficacy and safety of once-daily oral…”
Get full text

Evocalcet with vitamin D receptor activator treatment for secondary hyperparathyroidism by Takashi Shigematsu, Shinji Asada, Yuichi Endo, Takehisa Kawata, Masafumi Fukagawa, Tadao Akizawa

“…This ad hoc analysis of a previously conducted phase 3 head-to-head comparison study of evocalcet and cinacalcet in secondary hyperparathyroidism patients…”
Get full text

Corrigendum to “Efficacy of evocalcet in previously cinacalcet-treated secondary hyperparathyroidism patients,” [Kidney Int. Rep. 2021; https://doi.org/10.1016/j.ekir.2021.08.020] by Koiwa, Fumihiko, Tokunaga, Shin, Asada, Shinji, Endo, Yuichi, Fukagawa, Masafumi, Akizawa, Tadao

“…[This corrects the article DOI: 10.1016/j.ekir.2021.08.020.]…”
Get full text

Correction to: Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan by Tanaka, Tetsuhiro, Nangaku, Masaomi, Imai, Enyu, Tsubakihara, Yoshiharu, Kamai, Masatoshi, Wada, Michihito, Asada, Shinji, Akizawa, Tadao

“…In the original publication of the article, two sentences in the “Results” section were published incorrectly. The corrected texts are provided below:…”
Get full text

Efficacy and Safety of Evocalcet Evaluated by Dialysate Calcium Concentration in Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis by Shigematsu, Takashi, Asada, Shinji, Endo, Yuichi, Kawata, Takehisa, Fukagawa, Masafumi, Akizawa, Tadao

“…Evocalcet is a novel oral calcimimetic drug that has demonstrated similar efficacy to cinacalcet in regulating serum parathyroid hormone (PTH), calcium, and…”
Get full text

Minimally invasive removal of infected pacemaker lead by Hirata, N, Ohtake, S, Sawa, Y, Amemiya, A, Asada, S, Matsuda, H

“…A 37-year-old woman with sick sinus syndrome suffered complications with recurring local infection at the generator pocket. Repeated debridement and antibiotic…”
Get full text

Serial Transcardiac Lactate Metabolism in Post-reperfused Stunned Myocardium in Evolving Myocardial Infarction : 54th Annual Scientific Session of the Japanese Circulation Society by MISHIMA, MASAYOSHI, KODAMA, KAZUHISA, NANTO, SHINSUKE, HIRAYAMA, ATSUSHI, ASADA, SHINJI

“…To elucidate the relationship between lactate metabolism following reperfusion and restoration of left ventricular (LV) function, we assessed serial changes in…”
Get full text

Age-related changes in manganese superoxide dismutase activity in the cerebral cortex of senescence-accelerated prone and resistant mouse by Kurokawa, Tomonori, Asada, Shinji, Nishitani, Shinobu, Hazeki, Osamu

“…In this paper, we showed that the oxidative stress in brain of senescence-accelerated prone mouse 8 (SAMP8) at earlier stages was increased compared with that…”
Get full text

Serial transcardiac lactate netabolism in post-reperfused stunned myocardium in evolving myocardial infarction by MISHIMA, MASAYOSHI, KODAMA, KAZUHISA, NANTO, SHINSUKE, HIRAYAMA, ATSUSHI, ASADA, SHINJI

Get full text

Late reperfusion for acute myocardial infarction limits the dilatation of left ventricle without the reduction of infarct size by HIRAYAMA, A, ADACHI, T, KODAMA, K, ASADA, S, MISHIMA, M, NANTO, S, KUSUOKA, H, YAMAMOTO, K, MATSUMURA, Y, HORI, M, INOUE, M

“…While previous clinical studies have shown a possible beneficial effect of the reperfusion performed at a relatively late phase of acute myocardial infarction…”
Get full text